Article
Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Pathology, research and practice - 1 Aug 2021
Jiang Xingran, Hu Xiumei, Gu Yajuan, Li Yunlong, Jin Mulan, Zhao Hongying, Gao Ruixia, Huang Zhan, Lu Jun
Abstract excerpt
BACKGROUND: Homologous recombination repair gene (HRR) mutations have been proven to be effective biomarkers for PARP inhibitor therapy for metastatic castration resistant prostate cancer. However, the frequency of HRR mutations in patients with localized and locally advanced prostate cancer is still unclear. This study investigated the profile of HRR gene mutations in Chinese localized and locally advanced...
Topics
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- China
- Humans
- Male
- Middle Aged
- Mutation
- Neoplasm Grading
- Prostatectomy
- Prostatic Neoplasms
